EGFR and non-small cell lung carcinoma: A recent study suggested that EGFR-tyrosine kinase inhibitor (TKI, EGFR-TKI) adjuvant therapy for resectable NSCLC patients showed great improvement in the treatment outcome [prolong the disease-free survival (DFS)] [17].